NasdaqHealth CareBiological Products, (No Diagnostic Substances)OXFORDSHIRE, United Kingdom

Immunocore Holdings plc IMCR

Ask your AI

ADR: the number of shares per ADR isn’t known yetCIK 1671927

Insider trades, 12 mo

0 buys · 10 sells

$5.63M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

32 added · 19 trimmed

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Immunocore Holdings plc's latest quarterly report, compared with the one before.

Filed Nov 6, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Immunocore Holdings plc's latest quarterly report, compared with the one before.

Loading…

Insider trades

10 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Feb 18, 2026. Insiders have two business days to file.

Recent insider trades

Tina Amber St Leger CHIEF HR OFFICER	Feb 18 Form 4 ↗	Sale	−$32.4K 1,000 sh @ $32.35	-17.8%
David M. Berman HEAD OF R&D	Feb 18 Form 4 ↗	Sale	−$193.0K 5,965 sh @ $32.35	-17.8%
John Goll SVP, FINANCE & CAO	Feb 18 Form 4 ↗	Sale	−$22.6K 698 sh @ $32.35	-17.8%
Bahija Jallal CHIEF EXECUTIVE OFFICER, Director	Feb 18 Form 4 ↗	Sale	−$371.2K 11,474 sh @ $32.35	-17.8%
David M. Berman HEAD OF R&D	Dec 5, 2025 Form 4 ↗	Sale 10b5-1 plan	−$23.0K 572 sh @ $40.14	-32.8%

All IMCR insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

14.05M shares

70 funds report IMCR. Values checked against market prices.

Q3 2026. 8 new, 32 added to, 19 trimmed, 74 exited since Q2 2026.

Top 13F holders
#
1	Primecap Management Co 13F ↗	3.64M	$110.1M	-0.1%
2	Acadian Asset Management LLC 13F ↗	1.82M	$55.2M	+50.8%
3	FMR LLC 13F ↗	1.74M	$52.6M	-59.7%
4	BlackRock, Inc. 13F ↗	1.05M	$31.7M	+4.3%
5	Marshall Wace, LLP 13F ↗	614,728	$18.6M	+4.0%
6	Hudson Bay Capital Management LP 13F ↗	535,000	$16.2M	-9.3%
7	Principal Financial Group Inc 13F ↗	427,291	$12.9M	-12.0%
8	Massachusetts Financial Services Co 13F ↗	399,458	$12.1M	-1.9%
9	Jones Hill Capital LP 13F ↗	384,278	$11.6M	-25.1%
10	Candriam S.C.A. 13F ↗	366,492	$11.1M	-1.8%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds IMCR, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Immunocore Holdings plc and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Immunocore Holdings plc and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2021	41	—	14.11M	$597.8M
Q2 2021	45	+4	14.78M	$576.8M
Q3 2021	47	+2	16.65M	$617.4M
Q4 2021	49	+2	18.07M	$654.7M
Q1 2022	57	+8	19.74M	$590.1M
Q2 2022	66	+9	21.04M	$784.5M
Q3 2022	86	+20	26.52M	$1.2B
Q4 2022	104	+18	30.25M	$1.7B
Q1 2023	109	+5	34.78M	$1.7B
Q2 2023	120	+11	35.32M	$2.1B
Q3 2023	125	+5	36.95M	$1.9B
Q4 2023	133	+8	38.63M	$2.6B
Q1 2024	149	+16	42.84M	$2.8B
Q2 2024	139	-10	43.24M	$1.5B
Q3 2024	130	-9	45.30M	$1.4B
Q4 2024	115	-15	45.41M	$1.3B
Q1 2025	118	+3	47.30M	$1.4B
Q2 2025	135	+17	47.81M	$1.5B
Q3 2025	134	-1	49.18M	$1.8B
Q4 2025	151	+17	52.42M	$1.8B
Q1 2026	144	-7	52.46M	$1.6B
Q2 2026	136	-8	52.45M	$1.7B
Q3 2026	70	-66	14.05M	$425.8M

Each point is a quarter-end, from Q1 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (45258D105). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes9 in 12 mo 8-K events2 in 90 days Patents7 patents granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 8 in 12 mo Executive pay5 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials6 active FDA decisionsLatest Jun 27 IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Immunocore Holdings plc
Address: 90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, United Kingdom OX14 4RY
Phone: 01235 5430281
Fiscal year ends: Dec 31
Filer category: Large accelerated filer
Incorporated in: United Kingdom
Listed as: IMCR (Nasdaq)
Former names: Immunocore Ltd (until 2021)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$29.94−$0.54 (−1.76%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $27.82 · High $32.61Nov 13, 2026

Aug 13, 2026Low $27.82 · High $37.57Nov 13, 2026

Nov 13, 2025Low $27.79 · High $40.22Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.